Novavax Vaccine Appears 86% Effective Against U.K's COVID-19 Variant
Vaccine maker Novavax is waiting for its COVID-19 vaccine to be approved in the U.K., and is hopeful that U.S. approval will follow. NPR's Steve Inskeep speaks to Novavax CEO Stanley Erck.
[Copyright 2021 NPR]